Pharmacist-run lipid management program in rural Alabama

Donaldson, Amy R.; Andrus, Miranda R.

doi:10.1093/ajhp/61.5.493

Cited by 9 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past decade, several studies have been conducted in both hospital and ambulatory care settings to assess the effectiveness of pharmacistinitiated management programs for patients at high risk for cardiovascular disease. [4][5][6][7][8][9][10][11][12] These studies have shown improvements in clinical outcomes as well as increases in patient knowledge and drug self-management. They have also demonstrated the cost-effectiveness of the programs and have shown that patient satisfaction is higher in clinics managed by pharmacists than by physicians.…”

mentioning

confidence: 99%

“…19 Other studies have shown that collaboration of pharmacists with other health professionals improves clinical, economic, and humanistic outcomes. [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] In most of the above studies, 4-19 community pharmacist services were offered in the pharmacy, which patients frequently visited for cardiovascular risk factor assessment and drug therapy management. Our study differs from the others in two important respects: the intervention was delivered at a workplace, and the setting was a rural area.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Workplace-Based Cardiovascular Risk Management by Community Pharmacists: Impact on Blood Pressure, Lipid Levels, and Weight

et al. 2006

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Workplace-Based Cardiovascular Risk Management by Community Pharmacists: Impact on Blood Pressure, Lipid Levels, and Weight

et al. 2006

View full text Add to dashboard Cite

show abstract

“…These studies have demonstrated significant improvements in lipid parameters, improved adherence to lipid-modifying therapy, and increases in the proportion of patients achieving their target lipid goals. [26][27][28][29][30][31][32][33] Bogden et al conducted a randomized study of ambulatory care patients with total cholesterol levels greater than 240 mg/dL to assess the impact of a program encouraging teamwork between physicians and pharmacists on lipid levels and achievement of lipid goals. 33 A total of 95 patients were randomized to either usual care or the pharmacist/physician team.…”

Section: Management Of Dyslipidemiamentioning

confidence: 99%

Role of the Pharmacist in the Management of Dyslipidemia

Olson¹,

Potts

2006

Journal of Pharmacy Practice

View full text Add to dashboard Cite

C ARDIOVASCULAR DISEASE (CVD) is the leading cause of death in North America. 1 Dyslipidemia is one of a number of risk factors such as age, sex, hypertension, diabetes, and smoking that independently increases the risk for coronary disease. 2,3 More than half (50.7%) of adults older than 20 years have total cholesterol concentrations greater than 200 mg/dL. 1 Furthermore, just less than one half (45.8%) of the population has a low-density lipoprotein cholesterol (LDL-C) concentration greater than 130 mg/dL. 1 Given that LDL-C is the most atherogenic component of the lipid profile and the primary target for most therapeutic interventions, a significant number of patients require lipid-modifying therapy to decrease LDL-C to target values.There have been numerous large-scale, randomized clinical trials demonstrating the benefit of aggressive lipid-modifying therapy, particularly with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins"), in reducing the mortality and morbidity associated with CVD. 4-11 Patients with documented CVD derive the greatest benefit from aggressive lipid-modifying therapy. [4][5][6][7]11 Despite the abundance of literature supporting aggressive use of lipid-modifying therapy and the wide dissemination of clinical practice guidelines outlining management strategies for patients, particularly those at the greatest cardiovascular risk, studies indicate that a significant proportion of patients are not screened, initiated on appropriate therapy, or treated to target lipid levels. 12,13 Less than one half of the population, including those with documented CVD, who are eligible for lipid-modifying therapy receive it. 12,13 Furthermore, long-term patient adherence to these therapies after they are prescribed is poor. Approximately 50% of the population prescribed lipid-modifying therapy is still on it at 1 year. 14,15 In an effort to close the so-called treatment gap and address patient, physician, and health care system factors likely responsible for this gap, multidisciplinary teams that focus on cardiac risk factor management are essential to assist patients in achieving lipid targets. Pharmacists, as part of the multidisciplinary team, can play a vital role in assisting Dyslipidemia is one of a number of independent risk factors for cardiovascular disease. Numerous large-scale, randomized clinical trials demonstrate the benefit of aggressive lipid-modifying therapy in reducing the mortality and morbidity associated with cardiovascular disease. Despite these data and the wide dissemination of clinical practice guidelines outlining management strategies for patients with dyslipidemia, particularly those at the greatest cardiovascular risk, studies indicate that a significant proportion of patients are not screened, initiated on appropriate therapy, or treated to target lipid levels. Pharmacists, as part of the multidisciplinary team, can play a vital role in assisting in the management of patients with dyslipidemias. This article reviews published studies that have evaluate...

show abstract

“…A number of studies investigated the role of pharmacists in educating patients in various disease states. [7][8][9][10] In Australia, a prospective study was conducted to evaluate the role of pharmacists in asthma management. Pharmacists' responsibilities included patient education.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the clinical pharmacist's role in educating women about the benefits and risks of combined oral contraceptive pills in Jordan

Tahaineh

Alkyam

Al‐Sawalha

et al. 2020

J Pharm Health Serv Res

View full text Add to dashboard Cite

Objective To assess the pre‐intervention knowledge of women regarding the risks and benefits associated with the use of combined oral contraceptive (COC) pills. Then, to investigate the effect of an educational intervention on the knowledge of women about the risks and benefits of COC pills. Methods The study adopted two methodologies: a structured interview technique with women selected according to inclusion criteria, and a pre‐ and postintervention to measure the effect that clinical pharmacist's intervention may have had on them. Women who attended family‐planning clinics in the north of Jordan were interviewed using a structured questionnaire. The questionnaire included questions about demographics and questions to assess women's knowledge about COC pills. Then, women attended a 45‐min educational session about COC pills. One month later, the questionnaire was redistributed to the participants to assess any difference in their knowledge. Key findings Two hundred and ten women were enrolled in the study. One hundred and seventy‐seven women completed the study. At baseline, a quarter of the participants relied on other people's experiences as their main source of information with regards to COC pills. Moreover, 28.1% of women considered COC pills harmful. In addition, the results showed that the frequency of correct answers postintervention increased significantly compared to pre‐intervention (P < 0.005) including general information about COC pills and the relation between the use of COC pills and cancer. Conclusion Educational intervention introduced by clinical pharmacists improved the knowledge of women in Jordan regarding COC pills.

show abstract

Pharmacist-run lipid management program in rural Alabama

Cited by 9 publications

References 0 publications

Workplace-Based Cardiovascular Risk Management by Community Pharmacists: Impact on Blood Pressure, Lipid Levels, and Weight

Workplace-Based Cardiovascular Risk Management by Community Pharmacists: Impact on Blood Pressure, Lipid Levels, and Weight

Role of the Pharmacist in the Management of Dyslipidemia

Evaluation of the clinical pharmacist's role in educating women about the benefits and risks of combined oral contraceptive pills in Jordan

Contact Info

Product

Resources

About